



cancer conference
ncri
national cancer research institute

Programme 2008

2008 NCRI Cancer Conference
Sunday 5 October – Wednesday 8 October
The International Convention Centre, Birmingham



CME Accreditation: This conference has been approved by the Federation of the Royal College of Physicians of the UK for 20 external CPD credits

Programme Contents

Programme at a glance **3**

Symposia in detail **9**

The Conference features a number of high-quality symposia, each designed to attract a broad spectrum of cancer specialists.

Parallel sessions in detail **11**

This year's sessions cover a breadth of topics, spanning the central themes of: The Cancer Patient; Diagnosis and Therapy; The Cancer Cell; Epidemiology and Prevention; and Information and Delivering Cancer Care.

Workshops in detail **29**

The Conference also features a range of workshops designed to provide opportunities for development and networking.

Programme at a glance **Sunday**

12.30 – 14.45

Satellite workshop: metabolism and signalling in cancer

The Cancer Recognised Research Group in Northern Ireland (CRRG) Workshop

13.30 – 14.30

Public seminar and open forum: International comparisons and the impact on UK cancer care

Michel Coleman

London School of Hygiene and Tropical Medicine, University of London, UK

14.45 – 15.00

Welcome address

Sir Kenneth Calman

NCRI Chairman

15.00 – 15.40

Chromatin modifying enzymes: their function and role in cancer

Tony Kouzarides

Wellcome Trust/CR-UK Gurdon Institute of Cancer and Developmental Biology, University of Cambridge, UK



15.40 – 16.20

Normalising tumour vessels and microenvironment to treat cancer: from the bench to bedside and back

Rakesh Jain

Massachusetts General Hospital and Harvard Medical School, Boston, USA



16.20 – 18.10

Poster Session 1 and Refreshment Break

18.10 – 18.50

Dying with dignity: a contemporary challenge in palliative cancer care

Harvey Chochinov

University of Manitoba and Manitoba Palliative Care Research Unit, Canada



18.50 – 19.30

The causes and prevention of breast cancer

Valerie Beral

University of Oxford, UK



19.30 – 21:00

Opening Reception and Trade Exhibition

20.00 – 21.30

How does knowledge of genetic and life-style factors help us prevent breast cancer?

Breakthrough/Breast Cancer Campaign Open Discussion



Programme at a glance **Monday**

08.00 – 08.50

Educational Workshops

- BOA Educational Workshop
- BACR Educational Workshop

09.00 – 09.10

Introduction to the programme

Stan Kaye

Chair of the Programme Planning Committee

09.10 – 09.50

Controlling the cell cycle

Sir Paul Nurse

Rockefeller University, New York, USA



09.50 – 10.30

Preinvasive disease: catching it earlier, understanding it better, hitting it harder

Rebecca Fitzgerald

Hutchison-MRC Research Centre, Cambridge, UK



10.30 – 11.00

Refreshment Break and
Exhibition Viewing

11.00 – 12.30

Symposia

- **Living beyond cancer**
Hosted by Jessica Corner and Jane Maher
Macmillan Cancer Support, UK
- **Targeting vascular biology**
Hosted by Tim Eisen
Hutchison/MRC Research Centre, Cambridge, UK
- **The cell cycle in cancer**
Hosted by John Diffley
CR-UK London Research Institute, UK

12.30 – 15.00

Poster Session 2, Trade Exhibition, and
Lunch

13.00 – 14.00

Commercial Workshop

- K-RAS status in colorectal cancer: tailoring treatment to your patient – sponsored by Merck Serono

14.00 – 15.00

Workshops

- Alternative and innovative designs of Phase I/II trials
- How to publish and disseminate your results
- Leadership in scientific research
- NCRI data-sharing debate

15.15 – 17.30

Parallel sessions

- Colorectal cancer
- Depression and assisted suicide in cancer patients
- Ensuring equality and diversity in trial recruitment
- Genome stability in cancer
- Hormones and cancer
- Mechanisms of resistance
- Melanoma
- Paediatrics
- Understanding health behaviours relevant to cancer
- Proffered Paper Highlights (Session 1)

17.30 – 18.00

Refreshment Break

18.00 – 19.00

Clinical trials showcase

- **A prospective trial of computer-aided detection (CAD) in the UK Breast Screening Programme (CADET II)**
Fiona Gilbert
University of Aberdeen, UK
- **Cetuximab in advanced non-small cell lung cancer: the FLEX Trial**
Robert Pirker
Medical University of Vienna, Austria
- **Mature data from Medical Research Council (MRC) randomised trials in 2466 patients with Stage 1 seminoma**
Ben Mead
Southampton General Hospital, UK



19.00 – 21.00

Drinks Reception

19.00 – 21.00

Affymetrix Evening Symposium and Reception, featuring talks on “Integrated Approaches to Genomics”



20.00 – 22.30

Chairman’s Reception (by invitation)

Programme at a glance **Tuesday**

08.00 – 08.50

Educational workshops

- BOA Educational Workshop
- BACR Educational Workshop

09.00 – 09.40

Prostate cancer: a biologic approach to lethal disease

Howard Scher

Memorial Sloan Kettering Cancer Center, New York, USA



09.40 – 10.20

Inflammation and cancer: organ-specific regulation of cancer development

Lisa Coussens

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA



10.20 – 11.00

Refreshment Break and Exhibition Viewing

11.00 – 12.30

Symposia

- **Imaging: from molecules to patients**
Hosted by Kevin Brindle
University of Cambridge, UK
- **Novel therapies: from gene to drug**
Hosted by Paul Workman
The Institute of Cancer Research, Sutton, UK
- **The cost of cancer care**
Hosted by Mike Richards
National Cancer Director, NHS, UK

12.30 – 15.00

Lunch, Poster Session 3 and Trade Exhibition

13.00 – 14.00

Commercial Workshop

- Next generation sequencing : new frontiers in cancer genome biology – sponsored by Illumina

14.00 – 15.00

Workshops

- Facilitating clinical-basic science interfaces
- NCRN clinical research workshop
- How to write an effective grant proposal
- Making effective poster presentations

15.15 – 17.30

Parallel sessions

- Breast cancer
- Cell death
- Drug discovery and medicinal chemistry
- Improving the effectiveness of multidisciplinary team working
- MicroRNAs in cancer
- Molecular imaging for cancer
- Research challenges for rare cancers
- Screening and estimation of prognosis
- Using information to improve cancer care
- Proffered Paper Highlights (Session 2)

17.30 – 18.00

Refreshment Break

18.00 – 18.40

Tailoring adjuvant systemic therapy for breast cancer: dream or reality?

Martine Piccart

Institut Jules Bordet, Brussels, Belgium



18.40 – 19.20

Models of molecular diversity in breast cancer to guide marker guided therapy

Joe Gray

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA



19.30 – 23.00

Pfizer/BOA Excellence in Oncology Awards

20.00 – 20.30

Drinks Reception

20.30 – 02.00

Conference Dinner and Party

Programme at a glance **Wednesday**

09.00 – 11.15

Parallel sessions

- Cancer and older people
- Cancer vaccines
- Cell signalling
- Hepatocellular cancer
- Increasing public awareness of clinical trials
- Informatics
- Models of cancer
- Ovarian cancer
- Robotics and minimally invasive surgery
- Stem cells in cancer

11.15 – 11.45

Refreshment Break

11.45 – 12.25

Ras genes, Ras oncogenes and cancer

Mariano Barbacid

Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain



12.25 – 12.35

Closing Comments

Sir Kenneth Calman

Chair of the National Cancer Research Institute

12.35 – 13.30

Lunch Boxes Available

Symposia in detail **Monday**



Living beyond cancer

Hosted by Jessica Corner and Jane Maher
Macmillan Cancer Support, UK

- **Jessica Corner and Jane Maher**
Macmillan Cancer Support, UK
Introduction
- **Peter Rose**
University of Oxford, UK
Care of long term adult cancer survivors in primary care
- **Karen Luker**
University of Manchester, UK
Perspectives on returning to work after treatment for cancer
- **Julia Rowland**
National Cancer Institute, USA
Survivorship research: informing life and care after cancer

Targeting vascular biology

Hosted by Tim Eisen
Hutchison/MRC Research Centre, Cambridge, UK

- **Tim Eisen**
Hutchison/MRC Research Centre, Cambridge, UK
Introduction
- **George Thomas**
The Institute of Cancer Research, Sutton, UK
Title to be confirmed
- **John Heymach**
MD Anderson Cancer Centre, Houston, USA
Rational design of combination regimens using antiangiogenic agents
- **Adrian Harris**
Weatherall Institute of Molecular Medicine, University of Oxford, UK
Angiogenesis inhibitors, current drugs and new targets

The cell cycle in cancer

Hosted by John Diffley
CR-UK London Research Institute, UK

- **John Diffley**
CR-UK London Research Institute, UK
Introduction
- **Kim Nasmyth**
University of Oxford, UK
The cohesin ring cycle: how cells first build and then break sister chromatid cohesion during mitosis and meiosis
- **Bruce A Edgar**
Fred Hutchinson Cancer Research Centre, Washington, USA
Developmental control of cell cycle exit in drosophila
- **John Diffley**
CR-UK London Research Institute, UK
DNA replication and cancer: lessons from budding yeast

Symposia in detail **Tuesday**

Imaging: from molecules to patients

Hosted by Kevin Brindle
University of Cambridge, UK

- **Kevin Brindle**
University of Cambridge, UK
Introduction
- **Kevin Brindle**
University of Cambridge, UK
Detecting tumour responses to treatment with magnetic resonance imaging
- **Uwe Haberkorn**
University Hospital of Heidelberg, Germany
Biotechnology in nuclear medicine
- **Vasilis Ntziachristos**
Technische Universität München & Helmholtz Zentrum Munich Institute for Biological and Medical Imaging, Neuherberg, Germany
Advancing biological discovery with *in-vivo* photonic imaging

Novel therapies: from gene to drug

Hosted by Paul Workman
The Institute of Cancer Research, Sutton, UK

- **Paul Workman**
The Institute of Cancer Research, Sutton, UK
Introduction
- **Paul Workman**
The Institute of Cancer Research, Sutton, UK
Inhibitors of the HSP90 chaperone pathway
- **Carlos Garcia-Echeverria**
Novartis Institutes for Biomedical Research, Basel, Switzerland
Identification and development of NVP-BEZ235 - a dual PI3K/mTOR inhibitor in Phase I clinical trials
- **Garth Powis**
MD Anderson Cancer Center, Houston, USA
Hypoxic stress signalling as a target for cancer drug development

The cost of cancer care

Hosted by Mike Richards
National Cancer Director, NHS, UK

- **Mike Richards**
National Cancer Director, NHS, UK
Introduction: the cost of cancer symposium
- **Andrew Dillon**
National Institute for Health and Clinical Excellence, UK
The contribution of NICE to effective cancer care
- **Richard Tiner**
Association of the British Pharmaceutical Industry, London, UK
The cost of cancer care from an industry perspective
- **Jessica Corner**
Macmillan Cancer Support, UK
The costs of cancer to patients and society



Parallel sessions in detail **Monday**

Colorectal cancer

Hosted by Tim Maughan
Cardiff University, UK

- **Tim Maughan**
Cardiff University, UK
Introduction
- **Richard Houlston**
The Institute of Cancer Research, Sutton, UK
Emerging architecture of colorectal cancer predisposition
- **Trevor Dale**
Cardiff University, UK
Targeting the Wnt signalling pathway
- **Sabine Tejpar**
University Hospital Gasthuisberg, Leuven, Belgium
Predicting response to epidermal growth factor receptor inhibitors in colorectal cancer
- **Howard McLeod**
Washington University, St Louis, USA
Pharmacogenetics in colorectal cancer therapy

Proffered paper presentation:

- **Richard Hubner**
The Institute of Cancer Research, Sutton, UK
Investigating prognostic and predictive influences of germline polymorphisms on colorectal adenoma recurrence

Depression and assisted suicide in cancer patients

Hosted by Julia Addington-Hall
University of Southampton, UK

- **Julia Addington-Hall**
University of Southampton, UK
Introduction
- **Jane Walker**
University of Edinburgh, UK
'Better off dead': thoughts of death and suicide in cancer patients
- **Jesse Fann**
University of Washington, USA
Suicide rates in US cancer patients
- **Harvey Max Chochinov**
University of Manitoba and Manitoba Palliative Care Research Unit, Canada
The experiential landscape of terminal illness

Proffered paper presentations:

- **Louise Jones**
Marie Curie Palliative Care Research Unit, University College London, UK
Continuity of care in patients with cancer: development and evaluation of a complex intervention
- **Kate Jenkins**
Salisbury NHS Foundation Trust, UK
Implementing and evaluating a four tier model of psychological support. Results from a three year study



- **Eike Adams**
Oxford Brookes University, UK
A systematic review of the information needs of partners and family members of cancer patients

Ensuring equality and diversity in trial recruitment

Derek Stewart

Consumer Liaison Group, UK

- **Derek Stewart**
Consumer Liaison Group, UK
Introduction
- **Janet Dunn**
Warwick Medical School, University of Warwick, UK
Improving ethnic data collection for cancer
- **Tariq White**
University of Leeds, UK
Equality and diversity-part of everyone's business
- **Claire Foster**
University of Southampton, UK
Involvement of ethnic minorities in cancer research: experiences, barriers and recommendations

Proffered paper presentations:

- **Irene Tuffrey-Wijne**
St George's Hospital, University of London, UK
The experiences of people with learning disabilities who have cancer: an ethnographic study
- **Aileen Timmons**
National Cancer Registry, Cork, Ireland
Financial impact of a cancer diagnosis for patients and their families: a qualitative study among oncology social workers and patients

Genome stability in cancer

Hosted by Steve Jackson

Wellcome Trust/CR-UK Gurdon Institute of Cancer and Developmental Biology, University of Cambridge, UK

- **Steve Jackson**
Wellcome Trust/CR-UK Gurdon Institute of Cancer and Developmental Biology, University of Cambridge, UK
Introduction
- **Graeme Smith**
KuDOS Pharmaceuticals Ltd, Cambridge, UK
DNA repair pathways as targets for therapeutics
- **Alan D'Andrea**
Dana-Farber Cancer Institute, Boston, USA
Targeting DNA repair pathways in cancer therapeutics
- **Thanos Halazonetis**
University of Geneva, Switzerland
An oncogene-induced DNA replication stress model for human cancer development

Proffered paper presentations:

- **Ricky A Sharma**
University of Oxford, UK
DNA polymerase beta modulates sensitivity and resistance of colon cancer cells to oxaliplatin via DNA damage repair
- **Anthony Chalmers**
Brighton and Sussex Medical School, UK
KU-0059436 plus radiation as first line therapy for glioblastoma multiforme: rationale and phase I clinical trial protocol
- **Celine Cano**
Northern Institute for Cancer Research, Newcastle Upon Tyne, UK
Development of potent water-soluble inhibitors of the DNA-dependent protein kinase (DNA-PK)

Hormones and cancer

Hosted by Malcolm Parker

Imperial College London, UK

- **Malcolm Parker**
Imperial College London, UK
Introduction
- **Roland Schuele**
Klinikum der Universitat Freiburg, Germany
Androgen receptor function is regulated by histone demethylases: implication for prostate cancer
- **Donald McDonnell**
Duke University Medical Centre, Durham, USA
Validation of the estrogen related receptor as a therapeutic target in breast cancer
- **Arthur Zelent**
Leukaemia Research Fund Centre, The Institute of Cancer Research, London, UK
Deregulation of RAR γ and RAR γ -specific miRNAs in acute myeloid leukaemia

Proffered paper presentations:

- **Xenia Schmidt**
Bute Medical School, University of St Andrews, UK
Modelling estrogen receptor alpha-positive breast cancer by transformation of normal human mammary epithelial cells
- **Madryn Lake**
Imperial College London, UK
Non-invasive imaging of ER: coregulator interactions using luciferase fragment complementation
- **Martin K Thomsen**
The Institute of Cancer Research, London, UK
The role of Sox9 in prostate development and cancer

Mechanisms of resistance

Hosted by Robert Brown

Imperial College London, UK

- **Robert Brown**
Imperial College London, UK
Introduction
- **Tessa Holyoake**
University of Glasgow, UK
Characterisation and eradication of cancer stem cells in chronic myeloid leukaemia
- **Simak Ali**
Imperial College London, UK
Mechanisms of resistance to endocrine therapies in breast cancer
- **Frank Slack**
Yale University, New Haven, USA
MicroRNAs in development and cancer

Proffered paper presentations:

- **Charles Swanton**
Cancer Research UK London Research Institute, UK
Functional genomic annotation of microtubule stabiliser response defines chromosomal instability as a determinant of taxane sensitivity *in vivo*
- **Olivier E Pardo**
Imperial College London, UK
An FGFR inhibitor prevents chemoresistance *in vitro* and *in vivo*: a novel therapy for small cell lung cancer
- **Arvind Arya**
University of Liverpool, UK
The use of Nutlin-3 as a radiosensitiser in laryngeal carcinoma cells harbouring wild-type p53

Melanoma

Hosted by Xin Lu

Ludwig Institute for Cancer Research, Oxford, UK

- **Xin Lu**
Ludwig Institute for Cancer Research, Oxford, UK
Introduction
- **Colin Goding**
Ludwig Institute for Cancer Research, Oxford, UK
From stem cells to cancer: deciphering the Mitf code
- **Markus Frank**
Brigham and Women's Hospital, Boston, USA
Melanoma stem cells: implications for therapy
- **Vincenzo Cerundolo**
University of Oxford, UK
Harnessing NKT cells in cancer vaccination strategies
- **Elizabeth Patton**
University of Edinburgh, UK
Chemical-genetic approaches to identify novel compounds that sensitize melanocytes for cell death
- **Mark Middleton**
University of Oxford, UK
Defining who benefits from treatment for melanoma



Paediatrics

Hosted by Nazneen Rahman¹ and Sue Burchill²

¹The Institute of Cancer Research, Sutton, UK; ²Cancer Research UK Clinical Centre, St James's University Hospital, Leeds, UK



- **Nazneen Rahman**
The Institute of Cancer Research, Sutton, UK
Introduction
- **John Maris**
The Children's Hospital of Philadelphia, USA
The genetic basis of human neuroblastoma
- **Heinrich Kovar**
Children's Cancer Research Institute, Vienna, Austria
A NOTCH activation-dependent mechanism of tumour suppression involving p53 in Ewing's sarcoma
- **Mel Greaves**
The Institute of Cancer Research, London, UK
Clonal evolution in childhood acute lymphoblastic leukaemia

Proffered paper presentations:

- **Qian An**
University of Southampton, UK
Variable breakpoints target PAX5 in patients with dicentric chromosomes; a model for the basis of unbalanced translocations in cancer
- **Richard Scott**
The Institute of Cancer Research, Sutton, UK
Detailed constitutional epigenetic and copy number analysis of the 11p15 growth regulatory region in Wilms tumour by MS-MLPA
- **Tim Forshew**
Barts and The London School of Medicine and Dentistry, UK
Molecular genetic and epigenetic analysis of paediatric low-grade gliomas

Proffered paper highlights (session 1)

Hosted by Nic Jones¹ and Donna Johnstone²

¹Paterson Institute for Cancer Research, Manchester, UK; ²Manchester Cancer Research Centre, UK

- **Radoslaw Polanski**
University of Liverpool, UK
NME1 and NME2 regulate activities of p53 and MDM2
- **Frances Fuller-Pace**
University of Dundee, UK
The transcriptional coactivator p68 regulates expression of novel p53 isoforms that are critical for transcriptional activation by p53
- **Christopher Ricketts**
University of Birmingham School of Medicine, UK
Germline SDHB mutations and familial renal cell carcinoma
- **Wendy Cooper**
University of Birmingham, UK
The proapoptotic kinases MST1 and MST2 interact with RASSF2 translocating it from the nucleus to the cytoplasm

- **Aoife Shannon**
University of Manchester, UK
The MEK1/2 inhibitor AZD6244 (ARRY-142886) increases the therapeutic benefits of radiotherapy and inhibits the tumour hypoxia response in a lung tumour xenograft model
- **Jonathan Tyrer**
University of Cambridge, UK
Genetic susceptibility to ovarian cancer: results from the first stage of a genome-wide association study
- **Jo Morris**
King's College London, UK
DNA damage induces SUMO modification of BRCA1
- **Marissa V Powers**
The Institute of Cancer Research, Sutton, UK
Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumour-specific apoptosis

Understanding health behaviours relevant to cancer

Hosted by Roger Wilson

Consumer Liaison Group, UK



- **Roger Wilson**
Consumer Liaison Group, UK
Introduction
- **Willem van Mechelen**
VU University Medical Center, Amsterdam, The Netherlands
Physical activity interventions for people and places; self-responsibility or 'the Nanny State'?
- **Jane Wardle**
University College London, UK
New directions for behaviour change research in cancer prevention
- **Gerard Hastings**
Institute for Social Marketing and the Centre for Tobacco Control Research, University of Stirling and the Open University, UK
Title to be confirmed

Proffered paper presentations:

- **Victoria Benson**
University of Oxford, UK
Lifestyle factors and primary glioma and meningioma tumours in the Million Women Study cohort
- **Alan Casson**
University of Saskatchewan, Canada
Physical activity, obesity and risk for esophageal adenocarcinoma
- **Maria Traka**
Institute of Food Research, Norwich, UK
Consuming broccoli interacts with GSTM1 genotype to perturb oncogenic signalling pathways in the human prostate

Parallel sessions in detail **Tuesday**

Breast cancer

Hosted by **Mitch Dowsett**

The Royal Marsden Hospital, London, UK

- **Mitch Dowsett**
The Royal Marsden Hospital, London, UK
Introduction
- **Herve Bonnefoi**
Hospitaux Universitaires de Geneve, Geneva, Switzerland
Should we select specific chemotherapy regimens based on tumour molecular subtypes?
- **Laura van t'Veer**
The Netherlands Cancer Institute, Amsterdam, The Netherlands
Molecular profiling of early breast cancer guides treatment planning
- **Andy Tutt**
Guy's & St Thomas's NHS Foundation Trust, London, UK
Triple negative breast cancer: diagnosis or dustbin

Proffered paper presentations:

- **Mike Gonzalez**
MRC Cancer Cell Unit, Cambridge, UK
Geminin regulates DNA replication and predicts clinical outcome in breast cancer
- **Louise Li**
Northern Centre for Cancer Treatment, Newcastle, UK
Integration of HER-2 result into breast multidisciplinary decision making: results of a UK audit
- **Sarah Brown**
University of Leeds, UK
MR Imaging in breast cancer – results of the COMICE trial

Cell death

Hosted by **Eyal Gottlieb**

Beatson Institute for Cancer Research, Glasgow, UK

- **Eyal Gottlieb**
Beatson Institute for Cancer Research, Glasgow, UK
Introduction
- **Eileen White**
Rutgers University, Piscataway, USA
Role of autophagy in cancer progression and therapy
- **Michael Hengartner**
Institute of Molecular Biology, University of Zurich, Switzerland
Regulation of DNA damage-induced apoptosis by the HIF pathway in the nematode *C. elegans*
- **Xin Lu**
Ludwig Institute for Cancer Research, Oxford, UK
ASPP2 mediates senescence and inhibits autophagy and tumourgenicity induced by H-RasV12

Proffered paper presentations:

- **Afshan Ahmed**
University College London, UK
Regulation of cell death responses in hypoxia
- **Andrew Young**
Cancer Research UK Cambridge Research Institute, UK
Role for autophagy in the establishment of senescence
- **Dean Fennell**
Queen's University Belfast, Northern Ireland, UK
The BH3 peptidomimetic obatoclax restores absent mitochondrial death signals in cisplatin resistant non-small cell lung cancer

Drug discovery and medicinal chemistry

Hosted by Roger Griffin

Newcastle University, UK

- **Roger Griffin**
Newcastle University, UK
Introduction
- **Sir Tom Blundell**
University of Cambridge, UK
Exploring chemical and biological space: new approaches to drug discovery in oncology
- **Martin Noble**
University of Oxford, UK
Structure-function and structure-inhibition relationships in the CDK family
- **Bob Jackson**
Pharmacometrics Ltd, Cambridge, UK
Identifying the next generation of anticancer drug targets

Proffered paper presentations:

- **Anna Watson**
Northern Institute for Cancer Research, Newcastle upon Tyne, UK
Isoindolinone inhibitors of the MDM2-p53 protein-protein interaction: structure-activity studies
- **Hakim Djeha**
Antisoma Research Ltd, Welwyn Garden City, UK
A novel small molecule inhibits cancer cell proliferation *in vitro* and *in vivo* via activation of the protein kinase AMPK
- **Esther Bridges**
Lund University, Malmö, Sweden
Role of PI3K signalling pathway in modulating hypoxia response in neuroblastoma

Improving the effectiveness of multidisciplinary team working

Hosted by Lesley Fallowfield

University of Sussex, Brighton, UK

- **Lesley Fallowfield**
University of Sussex, Brighton, UK
Introduction
- **Lesley Fallowfield**
University of Sussex, Brighton, UK
The multidisciplinary team in clinical trials: a Cancer Research UK training initiative

- **Jane Blazeby**
University of Bristol, UK
Optimising decision-making in multi-disciplinary teams
- **Cath Taylor**
Adamson Centre for Mental Health, St Thomas' Hospital, UK
Improving the working lives of UK colorectal cancer teams: an evaluation of the Pelican team-based training programme

Proffered paper presentations:

- **Clarisa TP Choh**
United Bristol Healthcare Trust, UK
The role of upper gastrointestinal multidisciplinary teams in recruiting patients into randomised controlled trials
- **Liz Forbat**
Cancer Care Research Centre, University of Stirling, UK
Using patient involvement and patient experience to drive service change: a case example from cancer care

MicroRNAs in cancer

Hosted by Eric Miska

Wellcome Trust/CR-UK Gurdon Institute of Cancer and Developmental Biology, University of Cambridge, UK

- **Eric Miska**
Wellcome Trust/CR-UK Gurdon Institute of Cancer and Developmental Biology, University of Cambridge, UK
Introduction
- **Richard Gregory**
Children's Hospital, Harvard University, USA
Regulation of miRNA processing in embryonic stem cells and cancer
- **Eric Miska**
Wellcome Trust/CR-UK Gurdon Institute of Cancer and Developmental Biology, University of Cambridge, UK
MicroRNA regulatory networks
- **Reuwen Agami**
Netherlands Cancer Institute, Amsterdam, The Netherlands
Cancerous miRNAs and regulatory RNA binding proteins

Proffered paper presentations:

- **Edoardo Missiaglia**
The Institute of Cancer Research, Sutton, UK
MicroRNAs in childhood rhabdomyosarcoma
- **Saiful Miah**
University of Sheffield, UK
MicroRNA expression and profiling of bladder cancer
- **Katja Seipel**
Cardiff University, Wales, UK
RNA interference screen of the human Wnt signaling pathway

Molecular imaging for cancer

Hosted by Chris Nutting¹ and Frances Calman²

¹President of the British Oncological Association, UK; and ²Chairman of the Scientific Programme Committee, The Royal College of Radiologists, UK

- **Chris Nutting**
President of the British Oncological Association (BOA), UK
Introduction



- **Mikael Pittet**
Harvard Medical School, Boston, USA
Current methods of molecular imaging
- **Susan Galbraith**
Bristol-Myers Squibb, Princeton, USA
Molecular imaging in Phase 1 trials
- **Ilja Frank Ciernik**
Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland
Functional imaging applied to radiotherapy

Proffered paper presentations:

- **Andrew Gaya**
Mount Vernon Hospital, Northwood, Middlesex, UK
Inter-lesional variability of DCE-MRI response and changes in cardiac output following infusion of the vascular disruptive agent Combretastatin-A4-Phosphate (CA4P)
- **Martin Christlieb**
University of Oxford, UK
Developing new PET tracers and studying them with new techniques
- **Christophe Badie**
Health Protection Agency, Chilton, UK
Gene expression following ionising radiation: identification of biomarkers for dose estimation and prediction of individual response

Proffered paper highlights (session 2)

Hosted by Stan Kaye

Chair of the Programme Planning Committee, and Institute of Cancer Research and Royal Marsden Hospital, UK

- **Chris Parker**
The Institute of Cancer Research, Sutton, UK
Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer with respect to the outcome of radical treatment
- **Michael Brada**
The Institute of Cancer Research, Sutton, UK
A randomised trial of procarbazine, CCNU and vincristine (PCV) vs temozolomide (5-day or 21-day schedule) for recurrent high grade glioma (MRC BR12, ISRCTN83176944)
- **Usha Menon**
University College London EGA Institute for Women's Health, UK
Outcome of the prevalence screen in the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)
- **Astri Syse**
Cancer Registry of Norway, Oslo, Norway
A population-based study of marriage and divorce in survivors of adult cancers in Norway
- **Laura Gay**
University of Cambridge Pathology Department, UK
Effect of diet on APC mutation spectra in sporadic colorectal tumours from the EPIC-Norfolk Study
- **Henry Kitchener**
University of Manchester, UK
HPV testing in combination with liquid-based cytology in primary cervical screening: a randomised trial

- **Phil Quirke**
Leeds Institute of Molecular Medicine, UK
Prospective assessment of the quality of surgery in the MRC CLASICC trial evidence for variation in the plane of surgery in colon cancer, local recurrence and survival
- **Roger James**
The Kent Oncology Centre, Maidstone, UK
Long-term outcome of the first UKCCCR randomised trial of chemo-radiation for the treatment of epidermoid anal cancer

Research challenges for rare cancers

Hosted by Roger Wilson

Consumer Liaison Group, UK

- **Roger Wilson**
Consumer Liaison Group, UK
Introduction
- **Penny Wilson-Webb**
Rarer Cancers Forum, UK
The patient wants to see...
- **Peter Littlejohns**
National Institute for Health and Clinical Excellence (NICE), UK
The regulator's viewpoint
- **Jean-Yves Blay**
Université Claude Berard, Lyon, France
Collaboration is one route
- **Lucinda Billingham**
Cancer Research UK Clinical Trials Unit, University of Birmingham, UK
Alternative approaches to trial design

Screening and estimation of prognosis

Hosted by Bob Steele

University of Dundee, UK

- **Bob Steele**
University of Dundee, UK
Introduction
- **Phil Quirke**
University of Leeds, UK
Progress in the estimation of prognosis in cancer
- **Lawrence von Karsa**
International Agency for Research on Cancer, Lyon, France
Cancer screening in Europe
- **Julietta Patnick**
NHS Cancer Screening Programmes, Sheffield, UK
Cancer Screening in the UK

Proffered paper presentations:

- **Fahd Al-Mulla**
Kuwait University, Kuwait
Raf kinase inhibitor protein (RKIP) expression in colorectal cancer is associated with metastatic recurrence and reduced overall survival: from discovery to function
- **Judith Murphy**
National Cancer Registry Ireland, Cork, Ireland

A focus group study in Ireland of women's views, attitudes and knowledge of cervical screening and Human Papillomavirus (HPV)

- **Elizabeth Grunfeld**

King's College London, UK

Predictors of return to work in cancer survivors

Using information to improve cancer care

Hosted by David Forman

National Cancer Intelligence Network / Centre for Epidemiology and Biostatistics, University of Leeds, UK



- **David Forman**

National Cancer Intelligence Network / Centre for Epidemiology and Biostatistics, University of Leeds, UK

Introduction

- **Anna Gavin**

Queen's University Belfast, Northern Ireland, UK

Using registry data to monitor cancer strategy implementation

- **Elizabeth Davies**

King's College London, UK

Investigating cancer incidence, stage, treatment, and survival for different ethnic groups in South East England

- **Michel Coleman**

London School of Hygiene and Tropical Medicine, UK

Relevance of international survival comparisons for the UK

Proffered paper presentations:

- **Ken Lloyd**

Oxford Cancer Intelligence Unit, UK

Using information to improve cancer care at network level

- **Diana Bailey**

South West Public Health Observatory, Salisbury, UK

Do patients with oesophago-gastric cancer have a longer referral time and worse outcome if aged under 55? A prospective multicentre study

- **Ranjeet Jeevan**

Royal College of Surgeons of England, London, UK

Variation in the provision of immediate breast reconstruction in England

Parallel sessions in detail **Wednesday**

Cancer and older people

Hosted by Amanda Ramirez

King's College London, UK

- **Amanda Ramirez**
King's College London, UK
Introduction
- **Katrina Lavelle**
University of Manchester, UK
Non standard management of older women with breast cancer in the UK
- **Riccardo Audisio**
Whiston Hospital, Prescot, UK
Surgical mistreatment of older cancer patients
- **Martine Extermann**
Moffitt Cancer Center, University of South Florida, USA
Anticancer treatment: what do older patients want?

Proffered paper presentations:

- **Caroline Burgess**
Institute of Psychiatry, Kings College London, UK
Promoting early presentation of breast cancer: implementation and evaluation of a training programme for radiographers to deliver a psycho-educational intervention
- **Judith Mills**
The Institute of Cancer Research, Sutton, UK
How much do age, clinical and psychological factors contribute to fatigue following radiotherapy for early breast cancer? Evidence from the START Trials (UK Standardisation of Breast Radiotherapy)
- **Lorna Fern**
University College Hospitals, London, UK
Addressing delayed cancer diagnosis in primary care: Patterns of attendance and symptoms of teenagers and young adults seen in three general practices during one year

Cancer vaccines

Hosted by Peter Johnson

University of Southampton, UK

- **Peter Johnson**
University of Southampton, UK
Introduction
- **Robert Vonderheide**
University of Pennsylvania, Philadelphia, USA
Telomerase-based immunotherapy of cancer
- **Christian Ottensmeier**
University of Southampton, UK
DNA fusion gene vaccination, delivered with or without *in vivo* electroporation - a potent and safe strategy for inducing anti-tumour immune responses in prostate cancer

- **Frédéric Triebel**
Immutep SA, Paris, France
IMP321 and weekly paclitaxel as first-line chemo-immunotherapy in metastatic breast cancer (MBC)

Proffered paper presentations:

- **Munitta Muthana**
University of Sheffield, UK
Use of nanomagnets to enhance monocyte delivery of gene therapy to tumours
- **Mark Cobbold**
University of Birmingham, UK
Immunological targeting of the cancer phosphoproteome
- **Michael Salako**
The Institute of Cancer and CR-UK Clinical Centre, Barts and The London School of Medicine and Dentistry, London, UK
Targeting inflammatory cytokines using adenoviruses- gene delivery of biological therapies in ovarian cancer

Cell signalling

Hosted by Richard Marais

The Institute of Cancer Research, London, UK

- **Richard Marais**
The Institute of Cancer Research, London, UK
Introduction
- **Boris Bastian**
University of California, San Francisco, USA
Frequent somatic mutations of GNAQ in uveal melanoma and intradermal melanocytic proliferations
- **Margaret Frame**
University of Edinburgh, UK
Targeting invasion and metastasis
- **John Blenis**
Harvard Medical School, Boston, USA
ERK-MAP kinase signalling: biological context, cellular location, signal strength and duration dictate cell fate

Proffered paper presentations:

- **Stephanie Kermorgant**
Barts & The London School of Medicine, London, UK
C-Met oncogenic mutants sustain signals in the endosome and are protected against downregulation
- **Laura Harrington**
Weatherall Institute of Molecular Medicine, University of Oxford, UK
Cross talk between the VEGF and Notch signalling pathways in endothelial cells
- **Janine Erler**
The Institute of Cancer Research, London, UK
Lysyl oxidase secreted by hypoxic tumour cells is critical for pre-metastatic niche formation

Hepatocellular cancer

Hosted by Philip Johnson

University of Birmingham, UK

- **Philip Johnson**
University of Birmingham, UK
Introduction
- **Nathalie Wong**
Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China
Molecular biology of hepatocellular carcinoma
- **Riccardo Lencioni**
University of Pisa, Rome, Italy
The role of ablative therapies in hepatocellular carcinoma
- **Philip Johnson**
University of Birmingham, UK
New systemic approaches and trial design
- **Tim Meyer**
Royal Free Hospital, London, UK
Current and future trials in hepatocellular cancer

Proffered paper presentations:

- **Gary Beale**
Newcastle University, UK
Inhibition of ATM mediated DNA repair potentiates the cytotoxicity of DNA damaging ionising radiation in HCC cells

Increasing public awareness of clinical trials

Hosted by Hilary Blackburn and Joanna Eley

National Cancer Research Institute, London, UK

- **Hilary Blackburn and Joanna Eley**
National Cancer Research Institute, London, UK
Introduction
- **Jim Elliott**
Macmillan Cancer Support, UK
Increasing public awareness in research from the perspective of a cancer care and support charity
- **Louise Locock**
DIPEX, University of Oxford, UK
Personal experiences of clinical trials – a new website resource
- **Barbara Moore**
Wales Cancer Trials Network, Cardiff, UK
Research nurse perspective of increasing public awareness of clinical trials

Informatics

Hosted by Sir Mike Brady

University of Oxford, UK

- **Sir Mike Brady**
University of Oxford, UK
Introduction
- **Nicholas Ayache**
INRIA (French Research Institute of Computer Science and Automatic Control), Sophia-Antipolis, France
Personalizing *in silico* models of tumours with *in vivo* medical images

- **John Overington**
BioFocus DPI, London, UK
Informatics support for the discovery of new therapeutics
- **John Quackenbush**
Dana-Farber Cancer Institute and the Harvard School of Public Health, Boston, USA
Information integration approaches to genomic data analysis

Proffered paper presentations:

- **Speaker to be confirmed**
- **Philip Roy Quinlan**
University of Dundee, UK
INSPIRE: An integrated web based informatics infrastructure for automated analysis of laboratory and clinical data
- **Eva Morris**
University of Leeds, UK
A national perspective on the surgical management and outcomes of colorectal cancer liver metastases

Models of cancer

Hosted by Inke Nathke

University of Dundee, UK

- **Inke Nathke**
University of Dundee, UK
Introduction
- **Sir David Lane**
University of Dundee, UK
Studying the p53 pathway in Zebrafish
- **Caroline Hill**
CR-UK London Research Institute, UK
Using *Xenopus laevis* as a model system to understand transforming growth factor β signalling mechanisms and function
- **Alan Clarke**
Cardiff University, UK
Investigating the link between Intestinal stem cells and neoplasia

Proffered paper presentations:

- **Dhamayanthi Pugazhendhi**
University of Sheffield, UK
Modulation of human JAK/STAT pathway signalling by functionally conserved regulators and their potential role in myeloid leukemia
- **Rachel Brough**
The Institute of Cancer Research, London, UK
Using the Drosophila protein to further our understanding of BRCA2
- **Antonio Saha**
The Institute Of Cancer, CR-UK Clinical Centre, Barts and the London School Of Medicine and Dentistry, Queen Mary University of London, UK
Systematic optimisation of *in vivo* imaging of $\alpha v \beta 6$ in cancer

Ovarian cancer

Hosted by James Brenton

CR-UK Cambridge Research Institute, UK

- **James Brenton**
CR-UK Cambridge Research Institute, UK
Introduction
- **David Huntsman**
Vancouver Coastal Health Research Institute, Canada
Ovarian carcinoma subtypes are different diseases: implications for clinical and translational research
- **Iain McNeish**
Barts and the London School of Medicine, UK
Targeting cell cycle abnormalities in ovarian cancer using oncolytic adenoviruses
- **Elisabeth de Vries**
University of Groningen, The Netherlands
How to use new pathways to circumvent platinum resistance?

Proffered paper presentations:

- **Craig Carden**
The Institute Cancer Research, Sutton, UK
A Phase I study of AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor: results in patients with BRCA deficient ovarian cancer (BDOC)
- **Roshan Agarwal**
Imperial College London, UK
Alpha folate receptor (FOLR1) amplification and role in tumour growth independent of folate transport in ovarian cancer (EOC)
- **Quang-De Nguyen**
Imperial College London, UK
In vitro and *in vivo* evaluation of a novel 18F-labeled isatin as an apoptosis PET imaging tracer

Robotics and minimally invasive surgery

Hosted by David Neal

CR-UK Cambridge Research Institute, UK

- **David Neal**
CR-UK Cambridge Research Institute, UK
Introduction
- **Robin Kennedy**
St Mark's Hospital, Harrow, UK
Transforming outcomes of colorectal surgery in the laparoscopic era
- **John Primrose**
Southampton General Hospital, UK
Enabling minimally invasive liver surgery: case for a multidiscipline approach
- **Ash Tewari**
New York Presbyterian Hospital, Weill Cornell Medical Centre, USA
Cancer control and the preservation of neurovascular tissue: how to meet competing goals during robotic radical prostatectomy

Proffered paper presentations:

- **Dongbin Chen**
Imperial College London, UK
Development of a stereo image guidance system to assist robotic surgery of prostate cancer using augmented reality
- **Ros Eeles**
The Institute of Cancer Research, Sutton, UK
Identification of multiple novel prostate cancer predisposition loci
- **Dmitry Pshezhetskiy**
Imperial College London, UK
The SK1/S1P pathway as a potential diagnostic/prognostic marker in prostate cancer
- **Jeremy Clark**
The Institute of Cancer Research, Sutton, UK
Incidence, diversity and clinical relevance of ETV1 translocations in human prostate cancer

Stem cells in cancer

Hosted by Phil Jones

Hutchison-MRC Research Centre, Cambridge, UK

- **Phil Jones**
Hutchison-MRC Research Centre, Cambridge, UK
Introduction
- **Michael Clarke**
Stanford Comprehensive Cancer Centre, USA
What can we learn about self renewal and cancer therapy from the prospective isolation of cancer stem cells?
- **Christopher Heeschen**
Ludwig-Maximilians-University, Munich, Germany
Stem cells in pancreatic cancer
- **Tariq Enver**
University of Oxford, UK
Molecular regulation of normal and leukaemic human haemataopoietic stem cells

Proffered paper presentations:

- **Mays Jawad**
University of Nottingham, UK
In vitro chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia
- **Hidekazu Yamamoto**
University College London, UK
Characterisation of prostate stem-like cells from phosphatase and tensin homolog (PTEN) deficient mice
- **Osama Al-Assar**
University of Oxford, UK
Cancer stem cells are not more radioresistant than non-stem cells in cell lines from different origins with the exception of the MDA MB231 breast cancer cell line

Workshops in detail **Sunday**

Metabolism and signalling in cancer: the Cancer Recognised Research Group in Northern Ireland (CRRG) workshop

12.30 – 14.45

- **John Blenis**
Harvard Medical School, Boston, USA
mTOR signaling, metabolism and cell growth
- **Edwina Dobbin, Ciaren Graham, Robin Freeburn and Helen Wheadon**
Biomedical Sciences Research Institute, University of Ulster, Coleraine, Northern Ireland, UK
Regulated expression of the leukaemic oncogene Tel/PDGFR beta in embryonic stem cells identifies the key signalling pathways involved in its pathogenesis
- **VM Hodges, Z Shi, E Dunlop, MJ Percy, MK El-Tanani and TRJ Lappin**
Centre for Cancer Research and Cell Biology, Queen's University Belfast, Northern Ireland, UK
The role of the erythropoietin receptor in tumourigenesis
- **S van Schaeybroeck, JN Kyula, C Holohan, J Doherty, S Moulik, DB Longley and Patrick G Johnston**
Centre for Cancer Research and Cell Biology, Queen's University Belfast, Northern Ireland, UK
Src and ADAM-17 mediated shedding of TGF- α is an acute mechanism of resistance to chemotherapy
- **Suzanne McFarlane¹, Ashleigh McClatchey¹, Tony O'Grady², Gillian O'Hurley², Patrick G Johnston¹, Elaine Kay² and David JJ Waugh¹**
¹Centre for Cancer Research and Cell Biology, Queen's University Belfast, Northern Ireland, UK; ²Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland
CD44 initiates integrin-promoted cortactin and paxillin signaling to promote adhesion of metastatic breast and prostate cancer cells to bone marrow endothelium



Workshops in detail **Monday**

BOA educational workshop – ‘Meet the professor’

08.00 – 08.50

- **Robert Coleman**

Weston Park Hospital Sheffield, UK

Maintenance of bone health in cancer patients - a new priority for oncology

BACR educational workshop – Tissue microarrays and image analysis

08.00 – 08.50

Hosted by Liam Gallagher¹ and Elaine Kay²

¹University College Dublin, Ireland; ²Beaumont Hospital, Dublin, Ireland

- **Donal Brennan**

University College Dublin, Ireland

Commercial workshop - K-RAS status in colorectal cancer: tailoring treatment to your patient

13.00 – 14.00

Hosted by Timothy Maughan

Velindre Hospital, Cardiff, Wales

- **Sabine Tejpar**

University Hospital Gasthuisberg, Leuven, Belgium

Why is K-RAS status important?

- **Timothy Maughan**

Velindre Hospital, Cardiff, Wales

Impact of K-RAS status on outcome to treatment

- **Graeme Poston**

University Hospital Aintree, Liverpool, UK

Patients with liver-only metastases: the potential for "cure"

- **Rachel Butler**

All Wales Molecular Genetics Laboratory, Cardiff and Vale NHS Trust, Wales
K-RAS testing in practice



Alternative and innovative designs of Phase I/II trials

14.00 – 15.00

Hosted by Patrick Johnston

Velindre Hospital, Cardiff, Wales

- **Johann De Bono**

The Institute of Cancer Research, London, UK

The academic perspective

- **Andrew Hughes**

AstraZeneca Pharmaceuticals, Cheshire, UK

The industrial view

How to publish and disseminate your results

14.00 – 15.00

Hosted by Adrian Harris

British Journal of Cancer, UK

- **Stella Hurtley**
Science Magazine, Cambridge, UK
An editor's perspective
- **Tony Kouzarides**
Wellcome Trust/CR-UK Gurdon Institute of Cancer and Developmental
Biology, University of Cambridge, UK
An author's perspective
- **Steve Palmer**
Cancer Research UK, London, UK
Working with the media

Leadership in scientific research

14.00 – 15.00

Hosted by Sarah Burns

Cancer Research UK, London, UK

- **Lesley Yellowlees**
University of Edinburgh, UK

NCRI data-sharing debate

14.00 – 15.00

Hosted by Richard Begent

University College London, UK

- **Peter Dukes**
Medical Research Council (MRC) Research Career Awards, Research
Management Group, London, UK
- **Tim French**
Discovery Medicine, AstraZeneca, Macclesfield, UK
- **Matt Cockerill**
BioMed Central, London, UK
- **Sylvia Nagl**
University College London, UK
- **Kevin Johnson**
PanGenetics, Cambridge, UK

Workshops in detail **Tuesday**

BOA educational workshop – ‘Meet the professor’

08.00 – 08.50

- **Kevin Harrington**

The Institute of Cancer Research, London, UK

Interfaces between classical and molecular radiobiology

BACR educational workshop

08.00 – 08.50

Hosted by Val Brunton

University of Edinburgh, UK

- **Kurt Anderson**

Beatson Institute for Cancer Research, Glasgow, UK

Commercial workshop - Next generation sequencing - New frontiers in cancer genome biology

13.00 – 14.00

Details to be announced



Facilitating clinical-basic science interfaces

14.00 – 15.00

Hosted by Inke Nathke

University of Dundee, UK

- **Lisa Cotterill**

National Co-ordinating Centre for Research Capacity Development, Leeds, UK

- **Alastair Thompson**

University of Dundee, UK

- **Tim Illidge**

University of Manchester, UK

NCRN clinical research workshop

14.00 – 15.00

Hosted by David Cameron

National Cancer Research Network and Western General Hospital, University of Edinburgh, UK

How to write an effective grant proposal

14.00 – 15.00

Hosted by Simon Vincent

Cancer Research UK, London, UK

- **Ian Hart**

Chair of the Science Funding Committee, Cancer Research UK, London, UK

- **Iain McNeish**

MRC Senior Clinical Fellow, Barts and the London School of Medicine, UK

Making effective poster presentations

14.00 – 15.00

Hosted by Pete Moore

ThinkWrite Training, Bristol, UK